Bayer will focus on paying down debt and not make any major acquisitions in the next two or three years, the head of the ...

These launches are what Oelrich called “must-win battles” at Bayer as the Xarelto loss of exclusivity reaches “full swing” in ...

Oakmark Funds, advised by Harris Associates, released its “Oakmark International Fund” fourth quarter 2024 investor letter. A ...

The data uncover broad optimism as well as stark regional disparities and cultural obstacles in the West that must be ...

On the occasion of the 43rd J.P. Morgan Healthcare Conference in San Francisco ... has recently been initiated (outside of the US). The open-label, first-in-human, dose escalation study will ...

Bayer expects its pharmaceutical business to return to growth in 2027 as the launch new therapies is expected to offset ...

Germany is widely recognized as one of the leading countries in the pharmaceutical industry boasting a rich history of innovation cutting-edge research and global influence With its well-established i ...

Bayer is looking to accelerate its patient safety ... AI and machine learning technologies to pharmacovigilance provide us with an opportunity to further increase the efficiency of our ...

As the J.P. Morgan Healthcare Conference enters its second day, we're tracking presentations from GSK, Novartis, Sanofi, Eli ...

Germany’s Formycon and its licensing partner Klinge Biopharma have announced that the European Commission (EC) has granted ...